ARJUNA Therapeutics Partner with Oxford Researchers to Tackle Paediatric Brain Cancer

OXFORD, U.K. - EntSun -- OXFORD, UK & SANTIAGO DE COMPOSTELA, SPAIN —ARJUNA Therapeutics are proud to be collaborating with researchers at the University of Oxford on a new project funded by a prestigious research grant from Brain Research UK. This funding will support critical investigations into ARJUNA's lead molecule, Ag5, as a potential breakthrough treatment for paediatric high-grade glioma, one of the most challenging forms of childhood cancer.

The research will be conducted at the Department of Oncology, University of Oxford, within the laboratory of Professor Ester Hammond, PhD. Professor Hammond is a leading expert in the cellular response to hypoxia and DNA damage, making her lab uniquely positioned to evaluate Ag5's efficacy in the complex environment of paediatric brain cancer.

A New Chapter in Paediatric Oncology

This grant marks the official launch of ARJUNA Therapeutics' paediatric brain cancer programme. While the company continues to advance its clinical pipeline for adult glioblastoma and metastatic non-small cell lung cancer (NSCLC), this new initiative underscores a commitment to addressing the high unmet medical need in paediatric neuro-oncology.

More on EntSun News

• Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
• Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
• Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
• Cygnet Theatre Announces The Cast And Creative Team Of Stefano Massini's The Lehman Trilogy
• Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract

Paediatric high-grade gliomas are aggressive tumours located in the central reaches of the brain, often making surgical intervention impossible. Survival rates are very poor, with no significant therapeutic advances for many years. The Ag5 molecule offers a novel therapeutic approach designed to exploit specific metabolic vulnerabilities in these cancer cells while sparing healthy brain tissue.

Leadership Perspectives

"We are incredibly grateful to Brain Research UK for recognising the potential of this collaboration," said Professor Ester Hammond. "My team is eager to apply our expertise to evaluate Ag5. Paediatric high-grade gliomas are devastating for families, and finding a targeted, effective treatment is a priority."

Dr. Ross Breckenridge, PhD FRCP, CEO of ARJUNA Therapeutics, added:

"Expanding our research into paediatric oncology is a milestone moment for ARJUNA. By partnering with Professor Hammond and the world-class facilities at Oxford, we are bringing our lead molecule, Ag5, to the front lines of the fight against childhood brain cancer. This work runs in parallel with our existing programs in adult glioblastoma and lung cancer, broadening the horizon for what our technology can achieve."

More on EntSun News

• Cancun All Inclusive is ready for Spring Break 2026 with new Resorts, Exclusive Deals, activities and more!
• "EntryLevelActing.LA 2026 Promo" World Premieres in Hollywood's TCL Chinese Theatre 6pm PST 3/3/26
• 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
• iPOP Alum Madison Wolfe to Star in Ari Schlossberg's Upcoming Thriller "Young Blood"
• Ludex Partners With Certified Trading Card Association (CTCA) To Elevate Standards And Innovation In The Trading Card Industry

About ARJUNA Therapeutics

ARJUNA Therapeutics is a Europe-based biotech company dedicated to developing a new class of small-molecule medicines:  Therapeutic Molecular Clusters (TMC). Ag5 the first TMC, designed to target oxidative stress pathways in cancer cells, leaving non-cancer brain tissue unaffected, providing a potent and selective treatment option for hard-to-treat malignancies.

About Brain Research UK

Brain Research UK is the UK's leading dedicated funder of neurological research. They fund research into a large number of neurological conditions, with a focus on three areas of high unmet need: brain tumours, brain and spinal cord injury, and headache and facial pain.

Media Contacts:

• Oxford University Oncology Press Office: communications@oncology.ox.ac.uk
• ARJUNA Therapeutics Communications: info@arjunatherapeutics.com